JP2009541409A - ヘパラナーゼの抑制の為にデフィブロチドを使用する方法。 - Google Patents

ヘパラナーゼの抑制の為にデフィブロチドを使用する方法。 Download PDF

Info

Publication number
JP2009541409A
JP2009541409A JP2009517063A JP2009517063A JP2009541409A JP 2009541409 A JP2009541409 A JP 2009541409A JP 2009517063 A JP2009517063 A JP 2009517063A JP 2009517063 A JP2009517063 A JP 2009517063A JP 2009541409 A JP2009541409 A JP 2009541409A
Authority
JP
Japan
Prior art keywords
heparanase
defibrotide
cells
activity
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009517063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009541409A5 (enExample
Inventor
シナラ エカート
イリス フェッロ，ラウラ
イアコベッリ，マッシモ
Original Assignee
ゲンチウム エスピーエー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゲンチウム エスピーエー filed Critical ゲンチウム エスピーエー
Publication of JP2009541409A publication Critical patent/JP2009541409A/ja
Publication of JP2009541409A5 publication Critical patent/JP2009541409A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2009517063A 2006-06-27 2007-05-14 ヘパラナーゼの抑制の為にデフィブロチドを使用する方法。 Pending JP2009541409A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06425436A EP1872787A1 (en) 2006-06-27 2006-06-27 Use of defibrotide for the inhibition of heparanase
PCT/EP2007/054633 WO2008000549A1 (en) 2006-06-27 2007-05-14 Use of defibrotide for the inhibition of heparanase

Publications (2)

Publication Number Publication Date
JP2009541409A true JP2009541409A (ja) 2009-11-26
JP2009541409A5 JP2009541409A5 (enExample) 2010-06-17

Family

ID=37496823

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009517063A Pending JP2009541409A (ja) 2006-06-27 2007-05-14 ヘパラナーゼの抑制の為にデフィブロチドを使用する方法。

Country Status (6)

Country Link
US (2) US20090131362A1 (enExample)
EP (2) EP1872787A1 (enExample)
JP (1) JP2009541409A (enExample)
CA (1) CA2655522A1 (enExample)
IL (1) IL195971A0 (enExample)
WO (1) WO2008000549A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (it) 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
EP1982722A1 (en) * 2007-04-16 2008-10-22 Gentium S.p.A. Use of oligotide for the treatment of renal diseases
JP6069209B2 (ja) 2010-11-12 2017-02-01 ジェンティウム ソシエタ ア レスポンサビリタ リミタータ 移植片対宿主病（ｇｖｈｄ）の予防および／または治療に使用するためのデフィブロタイド
JP6198821B2 (ja) 2012-06-22 2017-09-20 ゲンチウム エス．アール．エル． デフィブロチドの生物学的活性を決定する為の、ユーグロブリンに基づく方法
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
MX2020001337A (es) 2017-08-03 2020-09-09 Jazz Pharmaceuticals Ireland Ltd Formulaciones que comprenden un acido nucleico en una alta concentracion.
MX2020010689A (es) 2018-04-12 2021-01-20 Jazz Pharmaceuticals Inc Defibrotida para la prevencion y tratamiento del sindrome de liberacion de citocinas y la neurotoxicidad asociada con la inmunodeplecion.
US20220023533A1 (en) 2018-12-07 2022-01-27 Jazz Phrmaceticals Ireland Limited Subcutaneous delivery of high concentration formulations
WO2021174039A1 (en) 2020-02-28 2021-09-02 Jazz Pharmaceuticals Ireland Limited Delivery of low viscosity formulations
WO2022234101A1 (en) 2021-05-06 2022-11-10 Jazz Pharmaceuticals Ireland Limited Defibrotide for the treatment and prevention of acute respiratory distress syndrome

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2154279A1 (de) * 1970-11-03 1972-05-25 Crinos Industria Farmaco Medikamente für das fibrinolytische System
IT1043823B (it) * 1970-11-03 1980-02-29 Prephar Procedimento per l estrazione di acidi nucleici da organi animali
US3899481A (en) * 1970-11-03 1975-08-12 Crinos Industria Farmaco Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
US4853221A (en) * 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170215B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per il trattamento di stati di insufficienza renale acuta
IT1170214B (it) * 1983-09-12 1987-06-03 Crinos Industria Farmaco Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) * 1984-02-16 1989-04-14 Crinos Industria Farmaco Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) * 1985-05-28 1987-09-15 Ajax Magnethermic Corporation Apparatus for overheating edges of skelp for the production of compression welded pipe
US5223609A (en) * 1986-04-17 1993-06-29 Crinos Industria Farmacobiologica S.P.A. Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
US4753221A (en) * 1986-10-22 1988-06-28 Intravascular Surgical Instruments, Inc. Blood pumping catheter and method of use
IT1231509B (it) * 1989-09-07 1991-12-07 Crinos Industria Farmaco Composizione farmceutica ad uso topico per la terapia della fragilita' capillare.
FR2654271B1 (fr) * 1989-11-06 1992-01-24 Moving Magnet Tech Actionneur electromagnetique monophase angulaire.
US6699985B2 (en) * 1991-08-21 2004-03-02 Arsinur Burcoglu Method of treating HIV infection and related secondary infections thereof
US5624912A (en) * 1991-08-21 1997-04-29 Burcoglu; Arsinur Method of treating HIV infection and related secondary infections with defibrotide
US5977083A (en) * 1991-08-21 1999-11-02 Burcoglu; Arsinur Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
IT1252174B (it) * 1991-12-09 1995-06-05 Crinos Industria Farmaco Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
DE69928778T2 (de) * 1999-06-08 2006-07-06 Gentium S.P.A., Villa Guardia Anwendung von Komplexen von kationischen Liposomen und Polydeoxyribonukleotiden wie Arzneimitteln
US20070037144A1 (en) * 2000-10-20 2007-02-15 Jay Wohlgemuth Leukocyte expression profiling
SE0003912D0 (sv) * 2000-10-24 2000-10-24 Abb Ab Industrirobot
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
WO2003027313A2 (en) * 2001-09-24 2003-04-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US6965025B2 (en) * 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP1325962A1 (en) * 2001-12-17 2003-07-09 Gentium S.p.A. A method for determining the biological activity of defibrotide
KR100509057B1 (ko) * 2002-10-23 2005-08-18 엘지전자 주식회사 진공청소기용 흡입노즐
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN5009009315; ＶＩＮＧＯＬＯ　Ｅ　Ｍ: ＡＣＴＡ　ＯＰＨＴＨＡＬＭＯＬＯＧＩＣＡ　ＳＣＡＮＤＩＮＡＶＩＣＡ Ｖ７７　Ｎ３, 1999, Ｐ３１５-３２０ *
JPN5009009316; ＤＡＶＩ　Ｇ: ＴＨＲＯＭＢＯＳＩＳ　ＲＥＳＥＡＲＣＨ Ｖ６５　Ｎ２, 1992, Ｐ２１１-２２０ *
JPN5009009317; ＢＥＬＣＡＲＯ　Ｇ: ＡＮＧＩＯＬＯＧＹ Ｖ４３　Ｎ１０, 199210, Ｐ７９３-８００, ＷＥＳＴＭＩＮＳＴＥＲ　ＰＵＢＬＩＣＡＴＩＯＮＳ，ＩＮＣ． *
JPN5009009318; ＢＥＬＣＡＲＯ　Ｇ: ＣＵＲＲＥＮＴ　ＴＨＥＲＡＰＥＵＴＩＣ　ＲＥＳＥＡＲＣＨ Ｖ４５　Ｎ５, 198905, Ｐ７２６-７３２, ＥＸＣＥＲＰＴＡ　ＭＥＤＩＣＡ *

Also Published As

Publication number Publication date
US20090131362A1 (en) 2009-05-21
WO2008000549A1 (en) 2008-01-03
CA2655522A1 (en) 2008-01-03
EP2035013A1 (en) 2009-03-18
EP1872787A1 (en) 2008-01-02
US20150196580A1 (en) 2015-07-16
IL195971A0 (en) 2009-09-01

Similar Documents

Publication Publication Date Title
JP2009541409A (ja) ヘパラナーゼの抑制の為にデフィブロチドを使用する方法。
Masseoud et al. Overview of hyperuricaemia and gout
JP6491089B2 (ja) シクロデキストリンを使用するための方法
JP2018203747A5 (enExample)
CN108697653B (zh) 小RNA-146a和纳米氧化铈缀合物促进伤口愈合和促进组织再生的用途
US20250241931A1 (en) Methods of treating a subject having clinically significant signs and symptoms associated with blood cell differentiation
US20100105758A1 (en) Use of an adenosine antagonist
JP2025511854A (ja) 非アルコール性脂肪肝疾患の治療
US20180214573A1 (en) Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways
KR20140050605A (ko) 간암의 재발, 악화 또는 전이 억제용 의약조성물
JP6574136B2 (ja) Ｅｇｆｒの発現をサイレンシングするためのｄｎａザイム
AT509045A4 (de) Verbindungen zur behandlung von asthma bronchiale
US20200339987A1 (en) Assays and methods for determining expression of the lect2 gene
EP1708692B1 (en) Dichloroacetate in combination with an inotrope for cardioprotection
EP3900736A1 (en) Composition comprising a dna-degrading enzyme for use in a method for the treatment of immunosuppression after acute tissue injury
US20220380765A1 (en) Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer
EP4291203A1 (en) Composition and method for reducing oxalate levels in patients receiving maintenance dialysis
WO2007096596A2 (en) Use of il-8 for the treatment of crohn' s disease
EP3236966B1 (en) Combination of raf inhibitors and taxanes
JP2006504769A (ja) 病理学的プロセスに関する遺伝子発現を制御するためのキナゾリノン組成物
EP1911449A1 (en) Anti-tumor agent comprising 6'-amidino-2'-naphthyl4- guanidinobenzoate or salt thereof
WO2018027149A1 (en) Methods of treating alport syndrome
RU2357752C2 (ru) Применение дезоксирибонуклеазы в качестве средства для снижения вязкости крови, лечения и профилактики заболеваний, связанных с ишемическим некрозом тканей
WO2020155534A1 (zh) 寡核苷酸分子及其在肿瘤治疗中的应用
EP4422642A1 (en) Glycoconjugated drug for the treatment of hepatocellular carcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100422

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120814

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121113

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130227